Patents by Inventor Yue-Mei Zhang

Yue-Mei Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 11591379
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY
    Publication number: 20230046728
    Abstract: In some embodiments, the invention relates to methods and reagents for the identification of compounds that traverse he cell membrane of an animal cell. In some embodiments, the invention provides additional methods for determining if a candidate compound that traverses an animal cell membrane is able to modulate an intracellular target, as well as reagents and kits for reagents and kits for performing the disclosed methods.
    Type: Application
    Filed: December 11, 2020
    Publication date: February 16, 2023
    Inventors: Amrita Singh Chandhoke, James Andrew Madsen, Yue-Mei Zhang, John Hanney McGee, Marco Peter Fekkes
  • Immunoglobulins and uses thereof
    Patent number: 11401315
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: August 2, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Cylcoalkenyl derivatives useful as agonists of the GPR120 and/or GPR40 receptors
    Patent number: 11230526
    Abstract: The present invention is directed to cycloalkenyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the GPR120 and/or GPR40 receptors. More particularly, the compounds of the present invention are agonists of GPR120 and/or GPR40, useful in the treatment of, for example, obesity, Type II Diabetes Mellitus, dyslipidemia, etc.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: January 25, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: James C. Lanter, Mark J. Macielag, Mark Wall, Michael P. Winters, Yue-Mei Zhang, Zhihua Sui
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20210253661
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors
    Publication number: 20210206822
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 8, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG
  • COLLECTIONS OF PEPTIDES, PEPTIDE AGENTS, AND METHODS OF USE THEREOF
    Publication number: 20210179665
    Abstract: The present disclosure provides powerful technologies for the development, production, characterization, and/or use of stapled peptide compositions. Among other things, the present disclosure provides strategies for defining amino acid sequences particularly amenable or useful for stapling, as well as technologies, reagents, and systems for developing, producing, characterizing, and/or using stapled peptides having such amino acid sequences.
    Type: Application
    Filed: August 20, 2019
    Publication date: June 17, 2021
    Inventors: John Hanney McGee, Ty Matthew Thomson, Sebastian Christof Theodor Wahl, Gregory L. Verdine, Raheleh Rezaei Araghi, Yue-Mei Zhang, Mark Joseph Mulvihill
  • Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors
    Publication number: 20210163566
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: February 5, 2021
    Publication date: June 3, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10968264
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Yue-Mei Zhang, Mark Wall
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10968265
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20210094998
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 1, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
  • Cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10961293
    Abstract: The present invention comprises compounds of Formula I. wherein: Z4, Z7, Z9, Z11, Z22, Z23, Z26, Z30, Z34, Z35, p, m, n, q, and BRIDGE are defined in the specification. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel compounds are useful for preventing, treating or ameliorating diseases and disorders, such as obesity, type 2 diabetes, the metabolic syndrome, insulin resistance, and dyslipidemia, among others.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: March 30, 2021
    Assignee: Janssen Pharmaceutics NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 10875902
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yue-Mei Zhang, Raul C. Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20200385439
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: August 21, 2020
    Publication date: December 10, 2020
    Inventors: Mark MACIELAG, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 10858413
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: December 8, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 10787495
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 16, 2019
    Date of Patent: September 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20200283491
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: March 16, 2020
    Publication date: September 10, 2020
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Substituted benzothiophenyl derivatives as GPR40 agonists for the treatment of type II diabetes
    Patent number: 10662170
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR40 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, R2, R3, R5, R6, W, and A are defined herein.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: May 26, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Hui Huang, Gee-Hong Kuo, Mark R. Player, Shyh-Ming Yang, Yue-Mei Zhang
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10640544
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: May 5, 2020
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Mark Macielag, Raymond J Patch, Rui Zhang, Martin A Case, Shamina M Rangwala, James N Leonard, Raul C Camacho, Michael J Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V Swanson, Wenying Jian, Yue-Mei Zhang, Mark Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20190367577
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 5, 2019
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI